Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DB-1310 |
Synonyms | |
Therapy Description |
DB-1310 is an antibody-drug conjugate (ADC) comprising an antibody targeting ERBB3 (HER3) linked to a DNA topoisomerase I inhibitor, which potentially inhibits growth of ERBB3 (HER3)-expressing tumors (PMID: 38632563). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DB-1310 | DB1310|DB 1310 | HER3 (ERBB3) Antibody 23 | DB-1310 is an antibody-drug conjugate (ADC) comprising an antibody targeting ERBB3 (HER3) linked to a DNA topoisomerase I inhibitor, which potentially inhibits growth of ERBB3 (HER3)-expressing tumors (PMID: 38632563). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05785741 | Phase Ib/II | DB-1310 | A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |